The effect of cardiac resynchronization on morbidity and mortality in heart failure.

By J. Cleland, J. Daubert, E. Erdmann, N. Freemantle, D. Gras, L. Kappenberger, L. Tavazzi. New England Journal of Medicine, 2005

6,316 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Cardiology and Cardiovascular Medicine, Complementary and alternative medicine

View Paper: https://www.semanticscholar.org/paper/e47eca9c090528f046ba16fd0f640cd1f177a91a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Complementary and alternative medicine

Citations in the corpus

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, positive): “In CARE-HF, at baseline, 25% of patients had a resting heart rate of ≤60 bpm.(262) – 264 If prevention of bradycardia is important, the effect of CRT will appear greater in trials where there is no device in the control group.”
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “Diagnosis or exclusion of HF Acute I A (212, 217-223, 245-250)”
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. (2005, background): “A beneficial effect on the composite of long-term mortality or allcause hospitalization has recently been demonstrated, as well as a significant effect on mortality.(171)”
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “Both for GDMT and other recommended drug treatment regimens, the reader is advised to confirm dosages with product insert material and to evaluate carefully for contraindications and drug-drug interactions.”
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2012, methodology): “There was a 25% reduction in all-cause mortality in RAFT (P ¼ 0.003), but mortality was not reduced in MADIT-CRT.”
2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). (2013, background): “56 However, in the extension study with a 37.4-month follow-up time, 46 there was a signiﬁcant 5.6% reduction intheabsoluteriskofdyingsuddenly.”
Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. (2012, background): “optimal medical treatment in patients with advanced heart failure (1,2,21,22).”
Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. (2006, methodology): “The original CARE-HF report suggested that most of the reduction in mortality was due to a decline in deaths due to worsening heart failure.(8) This is consistent with the concept that CRT leads to improved cardiac function and efficiency, which translates into an improvement in symptoms and outcome”
Dilated Cardiomyopathy (2007, positive): “In the CARE-HF study, CRT reduced all-cause mortality, and the survival benefit with CRT-D over an implantable ICD was consistent in a subgroup analysis of patients with ischemic and nonischemic DCM [62].”